BCL2 and B-cell chronic lymphocytic leukemia: It was demonstrated that splicing modulator E7107 affects the apoptotic pathway in human and murine CLL cells, thus favoring the BCL2 dependence and providing the opportunity for combinatorial treatment strategies with BCL2 inhibitors [83].